Oncolytic virus trial for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a virus-based treatment for glioblastoma that has come back after standard therapies. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have glioblastoma that has returned after previous treatment.
- You are between 18 and 70 years old.
- Your brain tumor can be seen on an MRI and is at least 1 centimeter wide.
- Your blood counts, kidney and liver function are normal or close to normal.
- You have not received certain cancer treatments (like chemotherapy, radiation, or targeted drugs) for at least a few weeks before joining.
- You agree to use birth control during the study and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
This trial tests a new treatment combining an oncolytic virus with a PD-1 inhibitor for people whose high-grade glioma has come back after standard therapy. The virus is injected directly into the tumor through a device placed in the head, and the drug helps your immune system fight the cancer cells.
This trial tests a new injection called VRT106 for people whose glioblastoma (a brain tumor) has come back or is growing. It uses a virus that may help the immune system attack the tumor. This study is for those who have not had a similar virus or gene therapy before.
This trial studies different treatment regimens for people with glioblastoma that is either newly diagnosed or has come back. It aims to find which treatment approach works best for controlling the tumor and improving outcomes.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
Hear when a new Glioblastoma (GBM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.